贝达药业：奥布替尼是一款BTK抑制剂，公司会关注该领域发展，目前尚无可公示的新药项目立项

Core Viewpoint - The company is exploring the development of drugs like Obrutinib, a BTK inhibitor, and is considering the integration of AI technology to enhance research and development efficiency [2]. Group 1 - The company confirmed that it is monitoring the development of Obrutinib but currently has no publicly disclosed new drug projects [2]. - The company recognizes the significant potential of artificial intelligence in areas such as target discovery, resistance mechanism identification, and real-world research [2]. - The company plans to actively incorporate AI-assisted technologies to improve research and development efficiency, thereby empowering drug development and clinical research [2].